Lucid Capital initiated coverage of Medicenna Therapeutics (MDNAF) with a Buy rating and C$4 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDNAF:
- Promising Developments in Medicenna Therapeutics Corp’s ABILITY-1 Trial Justify Buy Rating
- Medicenna to Engage Investors at ROTH Healthcare Conference
- Medicenna Therapeutics Announces Shareholder Meeting Results and Leadership Updates
- Medicenna to Present at H.C. Wainwright Global Investment Conference